Pneumonia Vaccine Education Intervention Study
Key facts
- Who runs it
- Geisinger Clinic
- Where
- Wilkes-Barre, United StatesSee the site
- Trial code
- Status
- Completed
- People taking part
- 141 people enrolled
- Started
- 6 May 2024
- Ended
- 26 Jan 2025
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Pneumococcal Vaccine Education
- Record updated
- 8 July 2025
Who can take part
- Age
- 18 years to 64 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Patients admitted to inpatient Family Medicine service with Type I and II Diabetes
- Patients who have not been previously vaccinated against pneumonia
- Patients meeting specific eligibility for Prevnar 20 vaccine: Over age of 65 OR have been diagnosed with any of the following: diabetes, chronic obstructive pulmonary disease, or asthma
Who cannot take part
- Patients that already received pneumonia vaccination in care history
- Patients with any active infections
- Patients allergic to any components of the vaccine
- Patients with pneumonia inpatient diagnosis at time of recruitment
- Patients who are in an immunosuppressed status
Where in United States
- Geisinger South Wilkes-BarreWilkes-Barre, United States
About the trial
What the trial wants to find out
The goal of this interventional clinical trial is to investigate the impact of medicine and pharmacy-led education on patient acceptance rates of Prevnar 20 pneumonia vaccination in patients eligible to receive the vaccine. The education intervention and subsequent option to get the vaccine will be done while the patient is admitted to inpatient care, prior to discharge. The main questions the study aims to answer are:
Read full original descriptionShow less
* Will supplemental education about the Prevnar 20 Pneumococcal vaccine influence patient acceptance rates when given a decision to receive it? * Is there any other statistically relevant qualitative reasoning behind the patient's final decision for accepting or refusing the vaccine?
The 2 groups in the trial
- ControlNo study treatment, for comparison
Patients randomized into this arm DO NOT RECEIVE Pneumococcal vaccine education prior to given the option to accept or refuse the vaccine.
- TreatmentTreatment being tested
Patients randomized into this arm RECEIVE Pneumococcal vaccine education prior to given the option to accept or refuse the vaccine.
Treatment: Pneumococcal Vaccine Education
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Physician-Pharmacy Collaboration to Increase Patient Acceptance of Pneumococcal Immunization Prior to Inpatient Discharge
- Record updated
- 8 July 2025